IRIS

Sfoglia per Rivista  

Opzioni
Vai a: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Mostrati risultati da 21 a 40 di 102
Titolo Data di pubblicazione Autore(i) File
Comparison of simple tests for the non-invasive diagnosis of clinically silent cirrhosis in chronic hepatitis C 1-gen-2006 Borroni, G.; Ceriani, R.; Cazzaniga, M.; Tommasini, M.; Roncalli, M.; Maltempo, C.; Felline, C.; Salerno, F.
Comparison of two different formulations of botulinum toxin A for the treatment of oesophageal achalasia. The Gismad Achalasia Study Group. 1-gen-1999 Annese, V; Bassotti, G; Coccia, G; D'Onofrio, V; Gatto, G; Repici, A; Andriulli, A.
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients 1-gen-2019 Pouillon, L; Danese, S; Hart, A; Fiorino, G; Argollo, M; Selmi, C; Carlo Stella, C; Loeuille, D; Costanzo, A; Lopez, A; Vegni, E; Radice, S; Gilardi, D; Socha, M; Fazio, M; Gonzalez-Lorenzo, M; Bonovas, S; Magro, F; Peyrin-Biroulet, L
Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors' reply 1-gen-2018 Goncalves, J; Magro, F; Danese, S; Lakatos, Pl; Ben-Horin, S
Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non‐elderly patients with inflammatory bowel disease—the IG‐IBD LIVE study. Authors' reply 1-gen-2022 Pugliese, Daniela; Privitera, Giuseppe; Armuzzi, Alessandro
Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer-authors' reply 1-gen-2017 Bonovas, S; Fiorino, G; Lytras, T; Nikolopoulos, G; Peyrin-Biroulet, L; Danese, S
Editorial: long-term safety and efficacy of certolizumab pegol for Crohn's disease 1-gen-2014 Cesarini, M; Danese, S
Editorial: should we abandon HCV genotype testing? Maybe 1-gen-2019 Torres, Mcp; Aghemo, A
Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis—a step towards precision medicine? 1-gen-2022 Solitano, Virginia; Armuzzi, Alessandro
Editorial: to facitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply 1-gen-2018 Bonovas, S; Lytras, T; Nikolopoulos, G; Peyrin-Biroulet, L; Danese, S
Editorial: withdrawal of anti TNF-alpha - are we ready for biological therapy cycling? 1-gen-2021 Pugliese, D; Armuzzi, A
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study 1-gen-2022 Pugliese, Daniela; Privitera, Giuseppe; Crispino, Federica; Mezzina, Nicolò; Castiglione, Fabiana; Fiorino, Gionata; Laterza, Lucrezia; Viola, Anna; Bertani, Lorenzo; Caprioli, Flavio; Cappello, Maria; Barberio, Brigida; Ricci, Chiara; Balestrieri, Paola; Daperno, Marco; Pluchino, Dario; Rizzello, Fernando; Scribano, Maria Lia; Sablich, Renato; Pastorelli, Luca; Manguso, Francesco; Variola, Angela; Di Sario, Antonio; Grossi, Laurino; Armuzzi, Alessandro; Null, Null
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open 1-gen-2020 Sands, Be; Armuzzi, A; Marshall, Jk; Lindsay, Jo; Sandborn, Wj; Danese, S; Panes, J; Bressler, B; Colombel, Jf; Lawendy, N; Maller, E; Zhang, Hy; Chan, G; Salese, L; Tsilkos, K; Marren, A; Su, Cy
Efficacy of a multistep strategy for Helicobacter pylori eradication 1-gen-2000 Gasbarrini, A; Ojetti, V; Armuzzi, A; Branca, G; Canducci, F; Torre, Es; Candelli, M; Pastorelli, A; Anti, M; Fedeli, G; Fadda, G; Pola, P; Gasbarrini, G
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis 1-gen-2006 Zocco, Ma; Dal Verme, Lz; Cremonini, F; Piscaglia, Ac; Nista, Ec; Candelli, M; Novi, M; Rigante, D; Cazzato, Ia; Ojetti, V; Armuzzi, A; Gasbarrini, G; Gasbarrini, A
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection 1-gen-2000 Cammarota, G; Cianci, R; Cannizzaro, O; Cuoco, L; Pirozzi, G; Gasbarrini, A; Armuzzi, A; Zocco, Ma; Santarelli, L; Arancio, F; Gasbarrini, G
Epithelial cell proliferation of the colonic mucosa in diverticular disease: a case-control study 1-gen-2005 Morini, S; Hassan, Cesare; Zullo, A; De Francesco, V; Burattini, O; Margiotta, M; Panella, C; Ierardi, E.
Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection 1-gen-2000 Cammarota, G; Cannizzaro, O; Ojetti, V; Cianci, R; Pastorelli, A; Armuzzi, A; Gentiloni, N; Gasbarrini, A; Pirozzi, G; Gasbarrini, G
Heat shock protein 47 is a new candidate molecule as anti-fibrotic treatment of Crohn's disease: authors' reply 1-gen-2010 Szabo, H; Fiorino, G; Danese, S
Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy 1-gen-1999 Rinaldi, V; Zullo, A; De Francesco, V; Hassan, Cesare; Winn, S; Stoppino, V; Faleo, D; Attili, Af
Mostrati risultati da 21 a 40 di 102
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile